PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study by Hernández, Norma A et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Research
PAR1 is selectively over expressed in high grade breast cancer 
patients: a cohort study
Norma A Hernández*1, Elma Correa1, Esther P Avila1, Teresa A Vela2 and 
Víctor M Pérez2
Address: 1Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Mexico City, Mexico and 2Patología Post-Mortem y Tumores 
Mamarios, Instituto Nacional de Cancerología, Mexico City, Mexico
Email: Norma A Hernández* - normahernandez21@yahoo.com; Elma Correa - elsy15@yahoo.es; Esther P Avila - akane_217@yahoo.com.mx; 
Teresa A Vela - terezan2002@yahoo.com; Víctor M Pérez - pesv2003@yahoo.com
* Corresponding author    
Abstract
Background: The protease-activated receptor (PAR1) expression is correlated with the degree
of invasiveness in cell lines. Nevertheless it has never been directed involved in breast cancer
patients progression. The aim of this study was to determine whether PAR1 expression could be
used as predictor of metastases and mortality.
Methods: In a cohort of patients with infiltrating ductal carcinoma studied longitudinally since 1996
and until 2007, PAR1 over-expression was assessed by immunoblotting, immunohistochemistry,
and flow citometry. Chi-square and log rank tests were used to determine whether there was a
statistical association between PAR1 overexpression and metastases, mortality, and survival.
Multivariate analysis was performed including HER1, stage, ER and nodes status to evaluate PAR1
as an independent prognostic factor.
Results: Follow up was 95 months (range: 2–130 months). We assayed PAR1 in a cohort of
patients composed of 136 patients; we found PAR1 expression assayed by immunoblotting was
selectively associated with high grade patients (50 cases of the study cohort; P = 0.001). Twenty-
nine of 50 (58%) patients overexpressed PAR1, and 23 of these (46%) developed metastases. HER1,
stage, ER and PAR1 overexpression were robustly correlated (Cox regression, P = 0.002, P = 0.024
and P = 0.002 respectively). Twenty-one of the 50 patients (42%) expressed both receptors (PAR1
and HER1 P = 0.0004). We also found a statistically significant correlation between PAR1
overexpression and increased mortality (P = 0.0001) and development of metastases (P = 0.0009).
Conclusion: Our data suggest PAR1 overexpression may be involved in the development of
metastases in breast cancer patient and is associated with undifferentiated cellular progression of
the tumor. Further studies are needed to understand PAR1 mechanism of action and in a near
future assay its potential use as risk factor for metastasis development in high grade breast cancer
patients.
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Background
Breast cancer is a health problem, specifically in develop-
ing countries, where early diagnosis systems are lacking
and mortality rates continue to increase. In Mexico up to
25 new cases of breast cancer are diagnosed everyday with
mortality rates reaching 15.7 per 100,000 in women
under 25 years of age [1,2]. Metastases to bone, lung, liver,
and the central nervous system represent the main com-
plication of treatment and also the main cause of death.
For example, breast cancer patients with pulmonary
metastases have an overall survival rate of 38% and 22%
by five and ten years respectively after the initial cancer
diagnosis [3,4].
Recent discovery of new factors involved in breast cancer
progression in vitro, are difficult to translate into diagnos-
tic tools to accurately identify patients at high risk of
metastasis. To improve treatment and survival of these
patients, a better molecular understanding of the early
mechanisms leading to metastases is required [5,6]. The
thrombin receptor, protease-activated receptor-1 (PAR1),
participates in a variety of biological processes, such as tis-
sue remodelling, inflammation, proliferation and angio-
genesis. PAR1 has long been thought to be involved in
tumour invasion, metastases associated with melanomas,
as well as with cancer of the breast, colon, lung, pancreas,
and prostate [7,8]. Although the exact role of PAR1 in
tumour cell invasion is not completely understood, it is
thought that PAR1 promote detachment and subsequent
migration of epithelial cancer cells from and through the
basement membrane, a key step in tumour metastases [9-
14]. Normal breast epithelial cells do not have the capac-
ity to migrate efficiently in response to chemotactic sig-
nals [9-14].
PAR1 is a G protein-coupled receptor. Four different PARs
have been identified: PAR1, PAR2, PAR3, and PAR4. PAR1
and PAR3 are activated by thrombin, PAR2 is activated by
tryptase or trypsin, and PAR4 is activated by both
thrombin and tryptase or trypsin. PAR1, the prototype
member of the PAR family, becomes activated when
thrombin cleaves a specific residue sequence (R41-S42)
within the receptor's N-terminal extracellular domain.
Synthetic peptides that correspond to the first few amino
acids of freshly cleaved N terminus (SFLLRN) can func-
tion as intramolecular agonists of PAR1. In several exper-
imental models (in vitro and in vivo), it has been shown
that thrombin enhances both tumour cell adhesion to
extracellular matrix proteins and the number of lung
metastases in animal models [11,12].
In established cancer cell lines, PAR1 expression levels
correlate directly with the degree of cancer invasiveness.
The human carcinoma breast cancer cell line MDA-MB-
231, which is highly invasive, expresses very high levels of
functional PAR1, PAR2, and PAR4. Another human carci-
noma breast cancer cell line, MCF-7, which is minimally
invasive, expresses only trace amounts of PAR1 and low
levels of PAR2 and PAR4. These data are consistent with
findings showing that high levels of PAR1 mRNA are
found in infiltrating ductal carcinoma, whereas very low
amounts are found in normal and premalignant atypical
intraductal hyperplasia [13-16].
Despite these advances, the role of PAR1 in breast cancer
cell invasion is not completely understood. It has been
suggested that thrombin indirectly induces cellular rear-
rangements by activating PAR1 and transactivating the
epidermal growth factor receptor (EGFR and/or HER2)
poor prognosis factors for breast cancer patients, which
exerts its effects exclusively through intracellular signals.
PAR1 has been specifically shown to be involved in the
migration and invasiveness of MDA-MB-231 cells via a Gi
protein-phosphatidylinositol 3-kinase dependent path-
way. Matrix metalloprotease-1 is responsible for activat-
ing the invasive functions of PAR1 [[13,14,17] and [18]].
Taken together, these findings prompted us to investigate
the role of PAR1 in the development of metastases in
breast cancer patients. Our aim was to determine whether
PAR1 expression patterns in patients diagnosed with infil-
trating ductal carcinoma correlate with long-term clinical
outcome. Development of metastases in these patients
was used to determine the biologic aggressiveness of the
cancer. We believe that cellular factors associated with
poor outcome, such as EGFR, HER2 and PAR1 overexpres-
sion, if associated with metastases or mortality, could
serve to identify patients at high risk to develop metastatic
breast cancer. We found significant correlations between
PAR1 overexpression and development of metastases and
increased mortality. Our data suggest that PAR1 plays an
important role in the development of metastases in breast
cancer patients. Further studies at the cellular level are
essential to clarify the precise role of PAR1 in breast cancer
patient's progression.
Methods
Patients
A cohort study was undertaken on a group of 136 female
patients from our Institution. They were admitted during
first three months of 1996 with a diagnosis of infiltrating
ductal carcinoma of the breast; inclusion criteria was lim-
ited to women virgin of any treatment elsewhere and con-
firmed diagnosis of ductal carcinoma; they were followed
longitudinally until 2007. After approval from our Institu-
tional board, and with a signed informed consent from
each patient, in all cases tissue blocks were taken from the
original biopsy used for diagnosis and prior any treatment
for PAR1 determination.Journal of Translational Medicine 2009, 7:47 http://www.translational-medicine.com/content/7/1/47
Page 3 of 10
(page number not for citation purposes)
The demographic, clinical, and pathological variables
examined were age, age at menarche, age at first birth, par-
ity, breastfeeding (considered positive, if were sustained
for more than 3 months), clinically and surgical positive
axillaries nodes, hormonal status and tumor size. The
pathologic size was determined after surgery based upon
the greatest dimension of the macroscopic specimen. All
patients were infiltrating ductal carcinoma for histological
type with a SBR ≥5–9. Classification of the histological
type and SBR were made by review of all available histo-
logical material by two independent pathologists, who
determined the diagnosis and determined tumour grade
according to Elston classification [19].
First diagnosis of metastases was noted as the time to first
appearance. In all cases diagnosis of metastases was con-
firmed by X-ray and/or CT-scan for lung metastasis,
gamma gram for bone metastases, ultrasonic detection or
CT-scan for Liver and CT-scan or magnetic resonance for
CNS. Up to four metastases sites were considered; we have
not collected tissue samples from all metastasis developed
in our cohort patients. Survival was recorded from time of
diagnosis to dead. The follow up period began at the date
of diagnosis. Patients were followed until death or cen-
sored from this analysis at the time of their last visit to our
Institution.
Immunoblotting
We used a 50 μm thick sample from each patient, taken
from serial paraffin sections. All samples were evaluated
by two independent pathologists; if necrosis or positive
margins were present the cases were not included in the
study. After paraffin removal, tissues were lysed using a
collagenase and trypsin buffers over night at 37°C and
suspended in lysis buffer (20 mM Tris HCl pH = 7.8, 50
mM NaF, 40 mM Na4P2O7, 5 mM MgCl2, 10 mM Na3VO4,
1% triton X-100, 0.1% SDS and 5 mM Benzamidine) sup-
plemented with 1 μg/ml each of pepstatin, leupeptin,
aprotinin and 2 μM phenyl methyl sulphonyl fluoride
(PMSF). After incubation of 20 minutes at 4°C, and
removal of cell debris, lysates were centrifuged at 15,000
g for 15 min at 4°C. Clear lysates were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE 12%),
blotted into a PVDF membrane (Amersham Life Science)
followed by immunoblotting to assess PAR1. As a positive
control we also assayed EGFR and HER2 expression, both
are well known poor prognostic factor for the outcome of
metastatic breast cancer patients, but also known as
downstream mediators of PAR1 activation [17,18].
We used a 1:2000 dilution of a mouse monoclonal anti-
body raised against aminoacids 42–45 of thrombin recep-
tor of human origin (Santa Cruz Bio-Technology). And we
also used an anti-EGF receptor mouse monoclonal anti-
body at same dilution (Upstate) which recognizes the
motif NAEYLR of the EGFR from mouse and human ori-
gin. Anti-rabbit polyclonal antibody raised against HER2
receptor from human origin (upstate) was also used at
1:1000 dilution. As a loading control we performed an
immunoblot using a 1:2000 dilution of a polyclonal anti-
body directed against Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) clone V-18 from Santa Cruz Bio-
Technology.
Enhanced Chemoluminescence was used to develop the
membranes (Amersham Life Science). PVDF membranes
were used in all cases (Amersham Life Science). Quantifi-
cation of the expression of the different mediators was cal-
culated with Aida software and presented as experimental
value - control value/control value × 100 where the con-
trol value was derived from lysates of cells mock exposed.
In order to validate and give strength to our results we
used two different human breast cancer cell lines as posi-
tive (MDA-MB-231) or negative (MCF-7) control for
PAR1 and EGFR expression as previously reported ([13],
data not shown).
Immunohistochemistry (IHC)
IHC staining was carried out for PAR and HER2. We used
an antibody that recognizes the N-terminal extracellular
loop of human thrombin receptor by immunohistochem-
istry with formalin-fixed, paraffin-embedded tissues
(Sigma); we also used a polyclonal antibody that recog-
nizes amino acids 1243–1255 from the human c-erbB-2/
HER2 (Upstate). We compared data obtained by IHC ver-
sus that one obtained by western blotting. Method was
described previously [20]; briefly the tissues were fixed in
10% buffered formalin, processed and embedded in par-
affin. Section 3-μm thick were then cut and dried for 12 h
at 37°C. One section from each block was stained with
H&E. The sections were de-paraffinised in xylene and re-
hydrated through graded concentrations of ethanol to dis-
tilled water. Incubating the sections in methanol and
hydrogen peroxidase for 30 minutes quenched endog-
enous peroxidase. Immunohistochemical staining was
performed by using the ABC system (Bio Genex, CA USA)
and DAB as substrate. Blocking serum was applied and
incubated for 15 minutes. Then we started the incubation
with the primary antibody diluted 1:500 for each anti-
body. Sections were incubated with the biotinylated sec-
ondary antibody and were developed using the
peroxidase substrate.
Each staining run included both positive and negative
control slides. The positive control slide was prepared
from tissue known to contain HER2; the negative control
slide was prepared from the same tissue block as the spec-
imen, however instead of using a primary antibody, this
one was incubated with an isotype-matched antibody.Journal of Translational Medicine 2009, 7:47 http://www.translational-medicine.com/content/7/1/47
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HER2 staining was scored utilizing a 3-point scoring sys-
tem; we considered positive staining, if we observed
strong continue and intense staining of the membrane in
more than 10% of the cells in the slide. PAR1 were scored
positive if any (weak or strong) cytoplasmic and/or mem-
branous invasive carcinoma cell staining was observed in
more than 10% of the cells in the slide. Slides were evalu-
ated for two different pathologists.
PAR1 Immunofluorescent staining by Flow Citometry (IF)
To determine PAR1 expression in paraffin-embedded sec-
tions from breast cancer patients we used same antibody
for western blotting. Tissue samples from the patients
were disaggregated into single cell suspensions (colla-
genase and trypsin 0.25%). Cells (1 × 106) were probed
with 1:500 anti-PAR1 dilution of the mouse monoclonal
antibody rose against amino acids 42–45 of thrombin
receptor of human origin (Thrombin R; ATAP2, Santa
Cruz Bio-Technology); and then treated with a goat anti-
mouse IgG (H+L) fluorescein conjugate (goat polyclonal).
FITC labelled cells were analyzed by flow citometry.
Statistical Analysis
The Chi-square or Fisher tests were used to determine dif-
ferences between proportions. Overall survival was
obtained by the PAR1 estimates by Kaplan-Meier method,
and differences between distributions were evaluated by
the log-rank test. A Cox Regression was performed includ-
ing clinical stage, Oestrogen receptor alpha and lymph
node status to evaluate PAR1 potential as an independent
prognostic factor. P values equal or less than 0.05 was
considered statistically significant.
Results
Over expression of PAR1
We assayed PAR1 expression in all samples (136 cases of
ductal carcinoma) of the study cohort by IHC, IF and
western blotting; however, we found PAR1 receptor
expression only in those patients with high grade. Nega-
tive results are not shown and we are presenting data from
the high grade cases we included in our cohort (50 cases).
The median follow-up time of the patients included in the
present study was 95 months (range: 2–130 months).
Western blot analysis of biopsy samples revealed that 29
of 50 (58%) patients with infiltrating ductal carcinoma of
the breast, expressed PAR1 (Figure 1a and 1b, Table 1).
Densitometric quantification of PAR1-immunoreactive
bands indicated that 20 of the 29 patients (69%) overex-
pressed PAR1 by more than 70% (Figure 1a and 1b) of
that expressed by a mock exposed invasive breast cancer
cell line (previously described in methods, data not
shown). Twenty one of 50 (42%) high grade patients did
not express PAR1 at all (Table 1 and Figure 1). We also
confirmed PAR1 expression in samples from our patients
using immunofluorescent staining for PAR1 present in the
surface of the cells (Figure 1c), and found 30 patients out
of 50 high grade breast cancer patients included in this
study (70%) express PAR1; highly significant when com-
pared with the rest of the group (P = 0.0001).
In regard to IHC data, as expected, more samples showed
PAR1-immunoreactivity by immunoblotting than the
ones assayed by IHC (Figure 1d); we found 25 samples
positive for PAR1 expression (50%) by IHC. Nevertheless,
all samples showing PAR1-immunoreactivity with IHC
were also positive when assayed by Western blotting.
Spearman correlation between PAR1 expression meas-
ured by IHC versus that measured by immunoblotting
was highly significant (P = 0.0005, r = 0.4767). Our anal-
ysis was carried out using the more sensitive and quanti-
tative immunoblotting results, but it is important to
mention, that all 25 tumor samples positive for PAR1
expression shown different degree of immune reactivity:
48.3% stained lightly, 24.1% moderately and 27.6%
strongly. PAR1 expression was found mainly in the entire
membrane although some cytoplasmatic staining was
also observed (Figure 1d); we found some degree of vari-
ation in the staining of PAR1 within the tumor; although
we were assaying a biopsy sample of the tumor; we have
been able to assayed some tumor samples (from the sur-
gery), initially found PAR1 positive; roughly we found
more than 50% of the tumors cells were immune reactive
for PAR1 staining; non significant staining was found in
the surrounding tumor microenvironment. (Figure 1d)
Regarding HER2 expression we found 5% tumors tested
were HER2 negative, 38.3% stained weakly, 34.8% mod-
erately and 28.2% strongly.
Correlations between HER2 and EGFR and PAR1 over 
expression
To determine whether there is an association between
HER2, EGFR1 and PAR1 expression, we assessed the
Table 1: PAR1 expression in breast cancer patients
Western blotting PAR1 immunoreactivity No. of patients* (%) Patients with metastases†(%)
Positive 29/50 (58%) 23/23 (100%)
Negative 21/50 (42%) 0
*Total number of patients (NT = 50)
†Number of patients with metastases (N = 23/50 [46%])Journal of Translational Medicine 2009, 7:47 http://www.translational-medicine.com/content/7/1/47
Page 5 of 10
(page number not for citation purposes)
PAR1 expression in breast cancer patients Figure 1
PAR1 expression in breast cancer patients. Western blots showing PAR and EGFR expression profiles of tumor biopsy 
samples from patients with infiltrating ductal carcinoma (Figure 1a and 1b). The blots are representative of three replicate 
tests. (c) A representative example of immunofluorecent staining of PAR1; Red line: background fluorescence (secondary anti-
body alone); green line: fluorescent shift attributable to PAR1 expression. Traces shown are representative of one of three 
independent measurements. (d) A tissue sample exhibiting PAR1 (visualized using ×10 and ×40, objective lens) and HER2 
strong membrane immunostaining; also shown: H&E and a negative control sections.Journal of Translational Medicine 2009, 7:47 http://www.translational-medicine.com/content/7/1/47
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expression of these markers in biopsy tissue obtained
from our patients (Figure 1). Twenty-five of 50 (50%)
samples expressed EGFR1 and HER2. Densitometry anal-
ysis revealed that 23 of the 25 (92%) samples overex-
pressed EGFR1 and HER2 by more than 80% compared to
controls (breast cancer cell lines as previously described;
data not shown). Twenty-one of 50 (42%) samples
expressed both PAR1 and EGFR1 and HER2. Statistical
analysis revealed a significant correlation between PAR1
and EGFR1 overexpression (Fisher exact two-tailed test, P
= 0.0004; Spearman Rank correlation, r = 0.5755, P =
0.0001). To evaluate the diagnostic potential of EGFR1
expression in relation to PAR1, we also measured the sen-
sitivity, specificity, and predictive powers of this associa-
tion. We found a sensitivity value of 0.72 (95%
confidence interval: 0.53 to 0.87), a specificity value of
0.81 (0.58 to 0.95), a positive predictive value of 0.84
(0.64 to 0.95), and a negative predictive value of 0.68
(0.46 to 0.85). In summary, if the breast cancer sample
expressed EGFR1, it was likely to also express PAR1.
PAR1 over expression and metastases development
Disease progressed rapidly in our study population (Fig-
ure 2). Of the 50 patients assessed, 23 (46%) developed
metastases, mostly within the first 24 months after receiv-
ing their cancer diagnosis. We found a significant associa-
tion between PAR1 overexpression and metastases: all 23
of these patients overexpressed PAR1 (Table 1, Figure 2).
Comparing this group with the group that did not develop
metastases and did not overexpress PAR1, Fisher's exact
test and a log rank test revealed a highly a reliable differ-
ence (P < 0.0001 and P = 0.00009, respectively). Although
23 of 29 (79%) of the patients overexpressing PAR1 devel-
oped metastases during the study, it is notable that 10
(35%) of these patients already had at least one metastasis
at the beginning of this study, indicating the advanced
clinical status of our patients. We also found a significant
correlation between EGFR1 overexpression and metas-
tases development in our patients (P < 0.0001, data not
shown). Also it was of interest to analyse the distribution
of metastases by organ and the order of appearance on a
Kaplan-Meier survival estimates of breast cancer patients overexpressing PAR1: those with and without metastases Figure 2
Kaplan-Meier survival estimates of breast cancer patients overexpressing PAR1: those with and without 
metastases. The survival of high-grade breast cancer patients overexpressing PAR1 (N = 29) is shown as a function of metas-
tases development. The differences between overall survival distributions were statistically significant (P = 0.0009).Journal of Translational Medicine 2009, 7:47 http://www.translational-medicine.com/content/7/1/47
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patient-by-patient basis. We found that 22 of 50 (44%)
patients developed their first metastasis in the following
locations: 10 of 22 (45%) in extra-axillary lymphatic nod-
ules, 6 of 22 (27%) in bone, 5 of 22 (23%) in lung and 1
of 22 (5%) in liver.
PAR1 overexpression and mortality
Twenty-two of 50 patients (44%) died of their disease.
Eighteen (36%) expressed PAR1. That is, of the 29 PAR1-
positive patients participating in our study, 18 (62%)
died. Fisher exact test analysis revealed a statistically sig-
nificant link between PAR1 overexpression and increased
mortality (P < 0.0001). This link was also supported by
Kaplan-Meier overall survival analysis (Figure 3). Differ-
ences between overall survival distributions were highly
significant as determined by a log-rank test (P = 0.0001).
We also found a significant correlation between EGFR
overexpression and mortality (P < 0.0001, data not
shown). In addition to examining positive association fac-
tors, we also analyzed our group of patients for usual
prognostic factors associated with tumour mortality in
breast cancer. Tumour size (≥5) and presence of pulmo-
nary metastases were significantly correlated, specifically
in groups of patients with or without PAR1 over-expres-
sion (P = 0.0004 and P = 0.0012 respectively).
Differences in demographic and clinical variables among 
PAR1-positive/negative patients
To determine the potential of PAR1 as a useful prognostic
factor for breast cancer patients, independent of the prog-
nostic factors for tumour mortality; we compared the
demographic, clinical, and pathological characteristics of
the 29 PAR1-positive patients to those of the 21 PAR1-
negative patients (Table 2). We found no major differ-
ences between the two groups regarding age, age at
menarche, age at first birth, parity, or breast-feeding.
Overall Kaplan-Meier survival estimates as a function of PAR1 expression Figure 3
Overall Kaplan-Meier survival estimates as a function of PAR1 expression. The overall survival of breast cancer 
patients is shown according to PAR1 overexpression. The differences between overall survival distributions were statistically 
significant (P = 0.0001).Journal of Translational Medicine 2009, 7:47 http://www.translational-medicine.com/content/7/1/47
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Moreover, we found no significant differences between
the two groups regarding the following clinical and path-
ological parameters: the number of affected lymphatic
axillary nodules (surgically identified [data not shown] or
clinically palpable), hormonal status, or tumour diame-
ter.
However, we did find a significant correlation between
PAR1 status and cancer invasiveness (P < 0.05). The dis-
ease of patients with PAR1-positive tumours tended to be
more clinically advanced than that of PAR1-negative
patients. Of the 29 patients who were over expressing
PAR1, 22 (76%) had IIIA-, IIIB-, or IV-stage breast cancer.
Only seven of 29 (24%) had I-, IIA-, or IIB-stage cancer. In
contrast, of the 21 PAR1-negative patients, only six (29%)
had IIIA-stage or greater cancer, whereas 15 (71%) had
IIB-stage or lower cancer.
We also performed a multivariate analysis including stage,
estrogen receptor (alpha), and lymph node status to eval-
uate PAR1 as an independent prognostic factor. Although
the small size of our cohort of patients, Cox regression
demonstrates highly significant p values for EGFR (P =
0.002), stage (P = 0.024), and absence of estrogen recep-
tor (P = 0.002). We did not find any significance for
lymph node status (P = 0.441).
Therapeutic treatment received by our patients
Our institution offers a diverse regimen of breast cancer
treatments that can impact disease outcome, particularly
the outcome of those in advanced stages of the cancer. To
determine whether our treatment schemes had contrib-
uted to our finding that PAR1 status affects the clinical sta-
tus of breast cancer, we grouped our patients by the
treatment they received and carried out statistical analy-
ses. All 50 high grade cases underwent radical resection of
the tumor. The patients received both systemic and local
therapy: systemic chemotherapy (mainly combinations of
doxorubicin [Adriamycin®] and cycloheximide) and/or
hormonotherapy (taxanes); and local chemotherapy and/
or radiotherapy before surgery). PAR1-positive and PAR1-
negative patients were treated similarly. There were no sig-
nificant differences in the types of therapy received by
PAR1-positive and PAR1-negative patients.
Discussion
In the present study, we demonstrated that PAR1 overex-
pression assayed by immunoblotting is associated with an
increased risk of metastases development and mortality in
patients with breast cancer (Table 1, Figures 1, 2, 3). All
patients with metastases overexpressed PAR1 (Figure 2).
Moreover, the majority of our PAR1-overexpressing
patients died during the course of this study (Figure 3).
Our data suggest PAR1 plays an important role in the
mechanisms underlying the development of metastases
[[8,10], and [14]]. Our findings are consistent with previ-
ous findings showing mRNA of PAR1 is expressed in pri-
mary breast cancer tissue; mediates the invasive potential
of certain breast cancer cell lines [13,15], and that it is
involved in the tumour progression [16].
We also found a significant correlation between the co-
overexpression of PAR1, EGFR1 and increased risk for
metastases (Figure 1 and 2). This link is not surprising,
since EGFR is a very well known poor prognostic factor in
breast cancer patients [[8,21] and [22]]. Furthermore it
had been shown that proteolytic activation of PAR1 by
thrombin induces persistent transactivation of EGFR and
ErbB2/HER2 in invasive breast carcinoma (23). Selectivity
of PAR1 expression in tumor samples, its invasive poten-
tial shown in breast cancer cell lines, and the important
role played by EGFR/HER2 as downstream transactivators
of PAR1, indeed explains the positive correlation we
found, between the expression of prognostic factors con-
veying poor disease outcome and poor tumour differenti-
ation [15,16,24]. Furthermore in our experience, PAR1 it
is not expressed at all or expressed at very low levels in
tumor samples from breast cancer patients with SBR = 8 as
previously assayed in our laboratory (data not shown). To
treat high risk population effectively and as early as possi-
ble during the course of their disease, we need a better
understanding of the mechanisms underlying tumour
progression.
Although the significant correlation between PAR1 over-
expression and increased mortality may be just a conse-
quence of tumour progression translated as the
Table 2: Distribution of demographic, clinical, and pathological 
variables of breast cancer patients as a function of PAR1 
expression
Variable PAR1*(+) PAR1* (-)
Age (years) 50 (23–77) 47 (31–58)
Age at menarche (years) 13 (11–16) 13 (12–15)
Age at first birth (years) 23 (18–34) 22 (19–33)
Parity 3 (0–12) 2 (0–8)
Breastfeeding (>3 months) 15/29 (52%) 14/21 (67%)
Clinically positive axillary nodes 19/29 (66%) 15/21 (71%)
Hormonal status†
Pre-menopausal 15/29 (52%) 11/21 (52%)
Post-menopausal 14/29 (48%) 10/21(48%)
Tumour diameter (cm) 7 (2–25) 6 (2–8)
ER‡ (+) 15/29 (52%) 10/21 (48%)
Total (NT = 50) 29 21
*Median (range or percentage) unless specified.
†Circulating estrogen and progesterone levels
‡Estrogen receptor statusJournal of Translational Medicine 2009, 7:47 http://www.translational-medicine.com/content/7/1/47
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establishment of metastases (Figures 2 and 3), this link is
still significant. It is well documented that visceral (lung,
liver) or CNS metastases result in the poorest prognostic
outcome for any given cancer [3,25-27]. PAR1 has been
shown to mediate the formation of pulmonary metastases
in animal models of cancer [12]. In the present study, we
found a very robust, significant correlation between PAR1
overexpression and the formation of pulmonary metas-
tases. Most of the patients developed their first metastases
within the first 24 months of being diagnosed; and the site
of these metastases tended to affect extra-axillary nodules.
Secondary metastatic sites were bone, lung, liver, and
CNS. Taken together, these findings implicate PAR1 as a
potential marker for aggressive cancer.
Our findings strongly implicate PAR1 as a prominent fac-
tor involved in tumour progression in breast cancer,
thereby supporting its use as potential prognostic factor
for invasive breast cancer. Indeed, we found that the clin-
ical status or stage of breast cancer in our patients was cor-
related with PAR1 overexpression: patients overexpressing
PAR1 in biopsy samples had more advanced disease than
did patients not expressing PAR1. This may have very
important implications at the cellular level [28,29], since
PAR1 may be first expressed in high-grade patients when
tumour progression is initiated. Thus, regular tracking of
PAR1 status may be useful to identify early on breast can-
cer patients at high risk for metastases.
Furthermore we have demonstrated despite the small size
of our cohort of patients, the multivariate analysis we per-
formed, shown highly significant p values for EGFR (P =
0.002), stage (P = 0.024), and absence of estrogen recep-
tor (P = 0.002). Our data strongly suggest PAR1 may be an
independent prognostic factor for breast cancer patients.
Although our sample of patients was very small, we are
confident that PAR1 is an equally accurate prognostic fac-
tor for metastases and mortality as are EGFR and HER2
[21,22,24], since comparison of PAR1-positive and PAR1-
negative patients revealed no significant differences in the
main prognostic parameters typically considered in breast
cancer (e.g., age, tumour diameter, hormonal status, etc).
Although treatments were diverse, we analysed this factor
and found no remarkable differences between treatment
types given to patients who showed PAR1 overexpression
and those who did not. Our data identifies PAR1 as a
potential prognostic factor for infiltrating ductal carci-
noma. Its consistent involvement in the progression of
breast cancer makes it an ideal prognostic tool only
assayed in cell lines [30,31]. However, because our find-
ings were based on a small sample of patients, the utility
of PAR1 as a prognostic tool must be further assessed in a
larger population of breast cancer patients, preferably
through prospective studies. We are currently conducting
further research to determine whether PAR1 can be used
as an independent prognostic factor of these kinds of
metastases in breast cancer patients with infiltrating duc-
tal carcinoma. If our hypothesis about PAR1 is correct, the
determination of PAR1 status can aid physicians in pro-
viding better follow-up therapy for these patients. Those
at high risk for metastases can be identified early, allowing
enough time for additional chemotherapy or surgical
resection of metastases with the aim of achieving long-
term survival or a longer disease-free period following sur-
gical resection. This would improve the overall survival of
high-grade breast cancer patients.
Conclusion
Our data suggest PAR1 is involved in the development of
metastases; showing a great potential as predictor of
metastases and mortality in high grade breast cancer
patients. Proteases have been implicated in tumor pro-
gression but PAR1 may be a good example of protease
effectors implicated in tumour invasion and metastasis
development and in a near future, PAR1 could become an
ideal candidate for assessing new targets for drugs in the
early diagnosis and treatment of metastasis in breast can-
cer patients.
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